Sandbox2

Revision as of 16:28, 19 March 2014 by Alonso Alvarado (talk | contribs)
Jump to navigation Jump to search

|

Overview

Wolff-Parkinson-White syndrome (WPW) is a syndrome of pre-excitation of the ventricles of the heart due to an accessory pathway known as the Bundle of Kent. The diagnosis is made when a patient with pre-existing WPW patern in the ECG developes an arrythmia which involves an accesory pathway. The treatment is focused on recovering sinus rythm. Atrial Fibrillation in a patient with WPW is lifethretening and should be managed urgently.

Causes

Life Threatening Causes

Life-threatening causes include conditions which result in death or permanent disability within 24 hours if left untreated. Wolff-Parkinson-White syndrome can be a life-threatening condition and must be treated as such irrespective of the underlying cause.

Common Causes

WPW is a congenic disease

Diagnosis

Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]

AVRT: AV reentrant tachycardia

 
 
 
 
 
 
 
 
 
 
 
 
Characterize the symptoms:
❑ Asymptomatic PalpitationsDyspnea
Fatigue Chest discomfort Lightheadedness
Syncope Polyuria

Characterize the timing of the symptoms:
❑ Onset
❑ Duration
❑ Frequency

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ Examine the patient

❑ Monitor the blood pressure
❑ Monitor the heart rate

❑ Order and monitor the ECG
❑ Assess and support ABC
❑ Give oxygen if needed
❑ Treat reversible causes if identified

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orthodromic AVRT

The impulse travels from the atrium to the ventricle through the AV node and returns to the atrium through the accesory pathway. 90-95% of WPW

❑ Narrow QRS complexes
❑ Ventricular rate between 150-250 bpm (or more) usually regular
❑ PR interval less than one half of the tachycardia RR interval

 
 
 
 
 
Antidromic AVRT

The impulse travels from the atrium to the ventricle through theaccesory pathway and from the ventricle to the atrium through the AV node. Less than 10% of WPW

❑ Wide QRS complexes
❑ Ventricular rate between 150-250 bpm (or more) usually regular
❑ PR interval more than one half of the tachycardia RR interval

 
 
 

Managment

Initial Management

Shown below is an algorithm summarizing the initial aproach to Wolff-Parkinson-White syndrome according to the 2003 ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias.[1]

 
 
 
 
 
 
 
 
 
 
 
 

❑ Determine blood pressure
❑ Determine heart rate
❑ If possible, catheter ablation (class I, level of evidence B

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable patient
 
 
 
 
 
Unstable patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Assess the ECG
 
 
 
 
 


❑ Catheter ablation (class I, level of evidence B
❑ Urgent electrical cardioversion (class I, level of evidence C

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Orthodromic AVRT
 
 
 
 
 
Antidromic AVRT
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment.

❑ Use Vagal maneuvers (class I, level of evidence B)

Carotid sinus massage
Valsalva maneuver


If not effective initiate IV AV nodal blocking agent

❑ Administer Adenosine, 6 mg (initial dose) that could be followed by 12 mg if initial dose not effective. Administer IV followed by 10 cc of saline solution (class I, level of evidence A)

If not effective

❑ Administer Verapamil, given in boluses of 5 mg every two to three minutes up to cumulative 15 mg (class I, level of evidence A)

If not effective

❑ Administer Procainamide, give intravenusly 20 to 50 mg/minute until the arrythmia is controlled or reach 17 mg/kg. Must monitor blood pressure every 5 to 10 minnutes (class I, level of evidence B)

 
 
 
 
 
Treatment.

❑ Administration of:

Ibutilide is the prefered treatment, administer 1 mg in an infusion over 10 minutes, if the tachycardia is not controlled give another 1 mg infusion over 10 minutes (class I, level of evidence B)
Procainamide, 20 to 50 mg/minute until the arrythmia is controlled or reach 17 mg/kg. Must monitor blood pressure every 5 to 10 minnutes (class I, level of evidence B)

Adenosine should be used with caution because may produce AF 6 mg (initial dose) that could be followed by 12 mg if initial dose not effective. Administer IV followed by 10 cc of saline solution

 
 
 

Wolff-Parkinson-White syndrome with Atrial fibrillation

Shown below is an algorithm summarizing the managment of Wolff-Parkinson-White syndromewith Atrial fibrillation according to the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.[2]

 
 
 
 
 
 
 
 
 

❑ Control ventricular response
❑ If possible: terminate AF
❑ If possible: catheter ablation of the accesory pathway (class I, level of evidence B)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable patient
 
 
 
 
 
 
 
Unstable patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

❑ Restore sinus rythm (class I, level of evidence C)

Ibutilide administer 1 mg in an infusion over 10 minutes, if the tachycardia is not controlled give another 1 mg infusion over 10 minutes (class I, level of evidence C)
Procainamide administer 20 to 50 mg/minute until the arrythmia is controlled or reach 17 mg/kg. Must monitor blood pressure every 5 to 10 minnutes (class I, level of evidence C)
Amiodarone, administer 5-7 mg/kg over 30-60 minutes (initial dose), then 1.2-1.8 g daily continuous infusion or in divided oral doses until 10 g total (class IIb, level of evidence B)

❑ Avoid AV blocking agents (class III, level of evidence B)

 
 
 
 
 
 
 
 
 
 

References

  1. 1.0 1.1 "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
  2. Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Le Heuzey, JY.; Kay, GN. (2006). "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (7): e257–354. doi:10.1161/CIRCULATIONAHA.106.177292. PMID 16908781. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources